|
Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Clinical research trials and Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy. Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy clinical trial. Participants frequently obtain the most expert healthcare available for their Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "Z" Clinical Trials Conditions > Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
For Condition: Breast Neoplasms,Osteoporosis
Status: Completed
Sponsor(s): Novartis Pharmaceuticals ,
Synopsis: This protocol is designed to compare the effect on bone of Zometa 4 mg every 6 months when given upfront versus delayed start ( based on a post-baseline BMD T- Score below –2.0 SD at either the lumbar spine or total hip, or any clinical fracture unrelated to trauma, or an asymptomatic fracture discovered at the month 36 scheduled visit) in stage I-IIIa postmenopausal women with hormone receptor positive breast cancer who will receive Femara 2.5 mg daily as an adjuvant therapy.
Details:
Eligibility:
Study Type: Interventional, Prevention, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/85 Years
Genders: Female
Protocol Entry Criteria: - Postmenopausal women with Stage I, II, or IIIa, ER and/or PR+ breast cancer with no clinical or radiological evidence of recurrent or metastatic disease before randomization. - Patients must have undergone complete tumor resection and margins of the resected specimen must be microscopically free of tumor. - In patients with tumor positive margins of the resected specimen, radiotherapy is mandatory.
Total Enrollment: 500
Location and Contact Information:
New Mexico Oncology Hematology, Ltd.
Albuquerque, New Mexico, 87109
United States
Bay Area Oncology
Tampa, Florida, 33607
United States
St. Joseph Regional Cancer Center
Bryan, Texas, 77802
United States
Swedish Cancer Institute
Seattle, Washington,
United States
New England Hematology/Oncology Associates
Wellesley, Massachusetts, 02481
United States
Oncology Partners Network
Cincinnati, Ohio, 45238
United States
Northern Virginia Oncology Group
Fairfax, Virginia, 22031
United States
Highlands Oncology Group
Springdale, Arkansas, 72764
United States
The Sarah Cannon Cancer Center
Nashville, Tennessee, 37203
United States
Methodist Cancer Center
Omaha, Nebraska, 68114
United States
Pacific Shores Medical Group
Long Beach, California, 90813
United States
Center for Oncology Research & Tx. PA
Dallas, Texas, 75230
United States
Space Coast Medical
Titusville, Florida, 32796
United States
VA Medical Center
San Juan, , 00927
Puerto Rico
Wilshire Oncology Medical Group
LaVerne, California, 91750
United States
Cancer Research Network, Inc.
Plantation, Florida, 33324
United States
Clinical Trials & Research Associates, Inc.
Montebello, California, 90640
United States
Elmhurst Memorial Hospital
Elhurst, Illinois,
United States
Hematology-Oncology Associates of Northern NJ
Morristown, New Jersey, 07962
United States
Odyssey Research Services
Bismark, North Dakota, 58501
United States
Cancer and Blood Institute of the Desert
Rancho Mirage, Colorado, 92270
United States
Charleston Hematology Oncology
Charleston, South Carolina, 29403
United States
Nashat Y. Gabrail MD Inc.
Canton, Ohio, 44718
United States
University of Pittsburgh Cancer Institute/Magee Womens Hospital
Pittsburgh, Pennsylvania, 15213
United States
Rockwood Clinic, PS
Spokane, Washington, 99220
United States
East Valley Hematology & Oncology
Burbank, California, 91505
United States
Eastern Connecticut Hematology/Oncology Associates
Norwich, Connecticut, 06360
United States
Kentuckiana Cancer Institute
Louisville, Kentucky,
United States
Virginia Physicians, Inc.- Oncology
Richmond, Virginia, 23294
United States
Metro Minnesota CCOP
St. Louis Park, Minnesota, 55416
United States
Pasco Pinellas Cancer Center
New Port Richey, Florida, 34652
United States
Robert R. Carroll, MD, PA
Gainesville, Florida, 32605
United States
Dayton Clinical Oncology Program
Dayton, Ohio,
United States
Louisiana Oncology Associates
Lafayette, California, 70506
United States
Cancer Specialists of South Texas
Corpus Christi, Texas, 78412
United States
Oncology Hematology Group of South Florida
Miami, Florida, 33176
United States
Hemoncare PC
Brooklyn, New York, 11235
United States
FL Community Cancer Center
Brooksville, Florida, 34613
United States
Redwood Regional Medical Group
Santa Rosa, California, 95403
United States
Cook Research Department at Spectrum Health
Grand Rapids, Michigan, 49503
United States
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, 21701
United States
Ocala Oncology Center
Ocala, Florida, 33479
United States
Hematology-Oncology Centers of the Northern Rockies, PC
Billings, Montana, 59101
United States
Physician Associates, Inc.
Cincinnati, Ohio, 45238
United States
Additional Information:
Study ID Numbers: CZOL446E US32;
Study Start Date: July 2002
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00050011
Other Breast Neoplasms Studies:
1. A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients with Metastatic Breast Cancer.
2. A Pilot Trial of Sequential Chemotherapy with Antimetabolite Induction, High-Dose Alkylating Agent Consolidation with Peripheral Blood Progenitor Cell Support, and Intensification with Paclitaxel and Doxorubicin for Patients with High-Risk Breast Cancer
3. Weight Loss Counseling for African American Breast Cancer Survivors
4. EPO906 Therapy in Patients with Advanced Breast Cancer
5. A Multimodality Treatment Approach to Patients with Inflammatory Cancer of the Breast and Locally Advanced Non-Inflammatory Stage III Breast Cancer and Stage IV Breast Cancer
Related Studies:
Other Breast Neoplasms Clinical Trials
Other Florida Clinical Trials
Other Gainesville Clinical Trials
Zometa - Femara Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women with Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
|
|
|
|
|
|
|
|